Souhaitez-vous accéder aux communiqués récents ?

Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite...

Key Financial Results Net income was $379 million, translating to diluted earnings per share ("EPS") of $4.74, up 39% from a year ago Adjusted EPS* increased 29% year-over-year to $5.84 Gross...

BRAMPTON, Ontario, July 30, 2026 (GLOBE NEWSWIRE) -- Loblaw Companies Limited (TSX: L) (“Loblaw” or the “Company”) announced today its unaudited financial results for the second quarter ended June...

R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis

TORONTO, July 02, 2026 (GLOBE NEWSWIRE) -- Consolidated Lithium Metals Inc. (TSXV: CLM | FRA: Z36 | OTCQB: JORFF) ("CLM" or the "Company") is pleased to announce the results of the Updated...

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

Global Application Specific Integrated Circuit (ASIC) Market Size, Share, Revenue Trends & Segment by Product, Application, Region and Forecast 2026-2035

Austin, TX, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes,...

Key Financial Results Net income was $356 million, translating to diluted earnings per share ("EPS") of $4.43, up 4% from a year ago Adjusted EPS* increased 9% year-over-year to $5.60 Gross...

TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- It’s time to put your best foot forward for a cause that matters. Registration for the 2026 Shoppers Drug Mart® Run for Women is now open, and Canadians...